30 completed, 15 terminated, 14 recruiting, 11 unknown. 82 Phase 2, 28 Phase 1, 4 Phase 3.
Follow Epithelial Ovarian Cancer: new trials by email Literature Review of Epithelial Ovarian Cancer trials Research Report on Epithelial Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [68Ga]BED003 - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-06-30 | 2026-09-15 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer EB-DUALNK, Cyclophosphamide, Fludarabine - Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-05-15 |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [18F]FPyQCP - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-02-19 | 2026-10-28 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-04 | 2026-03-18 |
| A Study of Isoquercetin in People With Ovarian Cancer Isoquercetin, Placebo - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 90 | 2026-01-22 | 2026-09-15 |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | AbbVie | 140 | 2025-11-21 | 2026-10-20 |
| Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT Prehabilitation - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Case Comprehensive Cancer Center | 1 | 2025-09-05 | 2026-09-15 |
| Surgery for Relapsed Ovarian Cancer in Precision surgery/chemotherapy, Iparomlimab/Tuvonralimab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 33 | 2025-07-01 | 2025-06-27 |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. TORL-1-23, Pegfilgrastim (drug) - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 230 | 2024-11-20 | 2025-12-23 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies ETX-19477 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 858 Therapeutics, Inc. | 120 | 2024-05-13 | 2026-03-27 |
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer RC88 - Primary Peritoneal Cancer, Fallopian Tube Cancer | Phase 2 | Completed | RemeGen Co., Ltd. | 43 | 2024-01-19 | 2026-01-07 |
| Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC Neoantigen polypeptide vaccine - Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital of Wenzhou Medical University | 10 | 2024-01-01 | 2024-04-02 |
| Study of AVZO-021 in Patients With Advanced Solid Tumors AVZO-021, Palbociclib, Fulvestrant - Advanced Solid Tumor, HR+/HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 430 | 2023-08-30 | 2026-09-28 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy Sodium Sulfate, Hydration, Cisplatin - Epithelial Ovarian Cancer, Acute Kidney Injury Due to Circulatory Failure | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 110 | 2023-05-01 | 2023-05-26 |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer KAND567, Carboplatin - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | Novakand Pharma AB | 18 | 2023-04-26 | 2025-06-08 |
| NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer XP-DC vaccinations - Epithelial Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Radboud University Medical Center | 10 | 2023-03-17 | 2025-11-18 |
Showing 20 of 82. Sign in to see all of them.
Carcinoma, Ovarian Epithelial (82) · Fallopian Tube Neoplasms (35) · Ovarian Neoplasms (26) · Colorectal Neoplasms (6) · Small Cell Lung Carcinoma (6) · Recurrence (5) · Stomach Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Transitional Cell (4) · Squamous Cell Carcinoma of Head and Neck (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3)
Adnexal Diseases (82) · Endocrine Gland Neoplasms (82) · Endocrine System Diseases (82) · Female Urogenital Diseases (82) · Female Urogenital Diseases and Pregnancy Complications (82) · Genital Diseases (82) · Genital Diseases, Female (82) · Gonadal Disorders (82) · Neoplasms by Histologic Type (82) · Neoplasms by Site (82) · Neoplasms, Glandular and Epithelial (82) · Urogenital Diseases (82) · Urogenital Neoplasms (82) · Carcinoma (81) · Genital Neoplasms, Female (81)
Carboplatin (16) · Paclitaxel (12) · Bevacizumab (7) · pembrolizumab (6) · liposomal doxorubicin (5) · Cisplatin (4) · Hyperthermic Intraperitoneal Chemotherapy (4) · CCV-AV protocol (3) · Cyclophosphamide (3) · Gemcitabine (3) · Nivolumab (3) · Topotecan (3) · denileukin diftitox (3) · 1-dodecylpyridoxal (2) · Drug Therapy (2)
Beijing Biotech (3) · Prima BioMed Ltd (3) · Blue Earth Diagnostics (2) · Eli Lilly and Company (2) · National Cancer Centre, Singapore (2) · Peking Union Medical College Hospital (2) · Shanghai Gynecologic Oncology Group (2) · The University of Texas Health Science Center at San Antonio (2) · University Health Network, Toronto (2) · pharmaand GmbH (2) · 23andMe, Inc. (1) · 858 Therapeutics, Inc. (1) · AGO Research GmbH (1) · AGO Study Group (1) · ARCAGY/ GINECO GROUP (1)
United States (42) · Canada (11) · China (11) · Germany (9) · Australia (8) · Belgium (6) · South Korea (6) · Austria (5) · France (5) · Singapore (5) · Spain (5) · Netherlands (4) · Denmark (3) · Sweden (3) · Italy (2)
Fernando Recio, MD (2) · Giuseppe Del Priore, MD (2) · James Mason, MD (2) · Peter Eisenberg, MD (2) · Alessandro D. Santin, MD (1) · Alexander Olawaiye, MD (1) · Amar Patel, MD (1) · Anders Jakobsen, MD, DMSc (1) · Andrea Jewell, MD (1) · Angeles Secord, MD (1) · Anna Karlsson, MD (1) · Anna-Clara Spetz Holm, MD, PhD (1) · Armando Sardi, M.D. (1) · Beihua Kong, M.D (1)
PMID 19169758, PMID 19819917, PMID 22014006, PMID 22564713, PMID 22960352, PMID 27330807, PMID 27908594, PMID 27998224, PMID 27998236, PMID 28453702, PMID 28528917, PMID 29342393, PMID 31046081, PMID 31685558, PMID 31791552, PMID 32689832, PMID 32994466, PMID 33554038, PMID 33941784, PMID 34350529, PMID 35121950, PMID 35149854, PMID 35170751, PMID 35262624, PMID 35397664, PMID 35712968, PMID 36200668, PMID 36608308, PMID 36608383, PMID 37185961, PMID 37236033, PMID 37407274, PMID 37648263, PMID 38022532, PMID 39178369, PMID 39516558, PMID 39651931, PMID 40210967, PMID 40461366, PMID 40481574, PMID 40525978, PMID 40700855, PMID 41213670
2008 (1), 2009 (1), 2015 (1), 2025 (1)